Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC3 known ✓ | O15379 | 1/20 | 0.50 |
| ▸ | HDAC4 known ✓ | P56524 | 1/20 | 0.50 |
| ▸ | HDAC1 known ✓ | Q13547 | 1/20 | 0.50 |
| ▸ | HDAC7 known ✓ | Q8WUI4 | 1/20 | 0.50 |
| ▸ | HDAC2 known ✓ | Q92769 | 1/20 | 0.50 |
| ▸ | HDAC10 known ✓ | Q969S8 | 1/20 | 0.50 |
| ▸ | HDAC11 known ✓ | Q96DB2 | 1/20 | 0.50 |
| ▸ | HDAC8 known ✓ | Q9BY41 | 1/20 | 0.50 |
| ▸ | HDAC6 known ✓ | Q9UBN7 | 1/20 | 0.50 |
| ▸ | HDAC9 known ✓ | Q9UKV0 | 1/20 | 0.50 |
| ▸ | HDAC5 known ✓ | Q9UQL6 | 1/20 | 0.50 |
| ▸ | PTGS2 known ✓ | P35354 | 1/20 | 0.49 |
| ▸ | GAA known ✓ | P10253 | 1/20 | 0.49 |
| ▸ | CES2 | O00748 | 1/20 | 0.64 |
| ▸ | CES1 | P23141 | 1/20 | 0.64 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.61 |
| ▸ | LMNA | P02545 | 2/20 | 0.61 |
| ▸ | NAPRT | Q6XQN6 | 1/20 | 0.61 |
| ▸ | P4HTM | Q9NXG6 | 1/20 | 0.61 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL29786333 | 1.00 | CES2 (0.64) | CES2CES1L3MBTL1LMNANAPRT | |
| SCHEMBL29407094 | 0.98 | — | — | |
| SCHEMBL1468 | 0.98 | — | — | |
| Methylene Chloride SCHEMBL28161272 | 0.91 | CES2 (0.59) | CES2CES1L3MBTL1LMNANAPRT | |
| Hydrochloric Acid SCHEMBL27723543 | 0.81 | KMT2A (0.72) | CES2CES1L3MBTL1LMNANAPRT | |
| 2-Picolinic Acid SCHEMBL890376 | 0.79 | LMNA (0.95) | CES2CES1L3MBTL1LMNANAPRT | |
| 2-Picolinic Acid SCHEMBL1469 | 0.79 | LMNA (0.95) | CES2CES1L3MBTL1LMNANAPRT | |
| 2-Picolinic Acid SCHEMBL30779159 | 0.79 | LMNA (0.95) | CES2CES1L3MBTL1LMNANAPRT | |
| 2-Picolinic Acid SCHEMBL29761294 | 0.79 | LMNA (0.95) | CES2CES1L3MBTL1LMNANAPRT | |
| 2-Picolinic Acid SCHEMBL28128752 | 0.79 | LMNA (0.95) | CES2CES1L3MBTL1LMNANAPRT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 437 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117088894-A | Fused ring conjugated macromolecule based on benzodipyrrole and preparation method and application thereof | 中国科学院化学研究所 | 2023-11-21 | — | — | CN | claimed |
| CN-116751157-A | Amplified preparation method of 2- (2-amino-5-bromo-benzoyl) pyridine | 上海再启生物技术有限公司 | 2023-09-15 | — | — | CN | claimed |
| CN-110304605-B | Method for preparing hydrogen by catalyzing formic acid with iridium-immobilized metal organic framework material | 华南理工大学 | 2023-02-14 | — | — | CN | claimed |
| CN-113979996-B | Phthalimide fluorescent probe for detecting copper ions, preparation method and application thereof, and copper ion detection method | 济宁医学院 | 2022-08-23 | — | — | CN | claimed |
| CN-113979996-A | Phthalimide fluorescent probe for detecting copper ions, preparation method and application thereof, and copper ion detection method | 济宁医学院 | 2022-01-28 | — | — | CN | claimed |
| CN-107199051-B | A kind of copper heterogeneous catalyst of pyridine coordination and preparation method thereof | 中国科学院福建物质结构研究所 | 2019-11-26 | — | — | CN | claimed |
| CN-110304605-A | A kind of method of the immobilized metal-organic framework materials catalysis formic acid hydrogen manufacturing of iridium | 华南理工大学 | 2019-10-08 | — | — | CN | claimed |
| CN-104628770-B | Preparation method of risedronate sodium | 漯河医学高等专科学校 | 2017-05-24 | — | — | CN | claimed |
| CN-102219796-A | Coordination polymer with selective ion exchange property, and applications thereof | UNIV TIANJIN NORMAL | 2011-10-19 | — | — | CN | claimed |
| CN-101967120-A | Preparation method of 2-p-chlorobenzyl pyridine | UNIV GUANGXI | 2011-02-09 | — | — | CN | claimed |
| US-20260109665-A1 | C7-FLUORO SUBSTITUTED TETRACYCLINE COMPOUNDS | TETRAPHASE PHARMACEUTICALS INC (US) | 2026-04-23 | — | — | US | disclosed |
| EP-4727944-A1 | [1,2,4]-TRIAZOLO[4,3-B]PYRIDAZINE DERIVATIVES USEFUL AS A MEDICAMENT | Perha Pharmaceuticals (FR) | 2026-04-22 | — | — | EP | disclosed |
| EP-4692065-A1 | PYRAZOLE COMPOUND AND HARMFUL ORGANISM CONTROL AGENT | Nissan Chemical Corporation (JP) | 2026-02-11 | — | — | EP | disclosed |
| CN-121248480-A | Synthesis method of 4,4' - (2-picolyl) bisphenol | 华东理工大学 | 2026-01-02 | — | — | CN | disclosed |
| CN-116751157-B | Amplified preparation method of 2- (2-amino-5-bromo-benzoyl) pyridine | 上海再启生物技术有限公司 | 2025-09-12 | — | — | CN | disclosed |
| EP-0099614-A2 | Nitro, amino and aroylamino-N-phenylpyridinamines and their use in a process for preparing pyrido(1,4)benzodiazapines | A.H. ROBINS COMPANY, INCORPORATED (US) | 1984-02-01 | — | — | EP | disclosed |
| EP-0074628-A2 | Ascochlorin derivatives; process for preparing the same and pharmaceutical composition containing the same | Chugai Seiyaku Kabushiki Kaisha (JP) | 1983-03-23 | — | — | EP | disclosed |
| US-4336380-A | FOR USE AS HYPOTENSIVE AGENTS | HOFFMANN-LA ROCHE INC. (US) | 1982-06-22 | — | — | US | disclosed |
| US-4276417-A | TREATMENT OF VASCULAR-CONDITION HYPERTENSION | HOFFMANN-LA ROCHE INC. (US) | 1981-06-30 | — | — | US | disclosed |
| EP-0007643-A1 | Oxadiazolotriazine derivatives | F. HOFFMANN-LA ROCHE & CO. Aktiengesellschaft (CH) | 1980-02-06 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260109665-A1 | C7-FLUORO SUBSTITUTED TETRACYCLINE COMPOUNDS | CBR1, CYP7A1, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16 | HDAC3 194/4885HDAC4 507/4885HDAC1 234/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.